Future Research Goals in Immunotherapy-Reference-Cited by-同舟云学术

Future Research Goals in Immunotherapy

Published:2019-07 Issue:3 Volume:28 Page:505-518
ISSN:1055-3207
Container-title:Surgical Oncology Clinics of North America
language:en
Short-container-title:Surgical Oncology Clinics of North America

Author:

Hulett Tyler W.,Fox Bernard A.,Messenheimer David J.,Marwitz Sebastian,Moudgil Tarsem,Afentoulis Michael E.,Wegman Keith W.,Ballesteros-Merino Carmen,Jensen Shawn M.

Funder

Bristol-Myers Squibb

PerkinElmer

Macrogenics

Definiens/AstraZeneca

OncoSec

NanoString

Viralytics

Janssen/Johnson and Johnson

Quanterix

Shimadzu

Deutsche Forschungsgemeinschaft

Publisher

Elsevier BV

Subject

Oncology,Surgery

Reference93 articles.

1. Adoptive cell transfer therapy following non-myeloablative but lymphodepleting chemotherapy for the treatment of patients with refractory metastatic melanoma;Dudley;J Clin Oncol,2005

2. IL-2: the first effective immunotherapy for human cancer;Rosenberg;J Immunol,2014

3. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer;Brahmer;N Engl J Med,2012

4. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia;Grupp;N Engl J Med,2013

5. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors;Kochenderfer;Nat Rev Clin Oncol,2013

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. DHX37 Impacts Prognosis of Hepatocellular Carcinoma and Lung Adenocarcinoma through Immune Infiltration;Journal of Immunology Research;2020-12-30

2. Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival;International Journal of Cancer;2019-12-02